Pricing Log in Create free account

Krystal Biotech, Inc. (KRYS) vs TG Therapeutics, Inc. (TGTX)

Krystal Biotech, Inc. and TG Therapeutics, Inc. are both Biotechnology companies. Krystal Biotech, Inc. is the larger, with a market value of $9.8B against $8.6B — 1.1× the size. TG Therapeutics, Inc. trades at the lower P/E: 17.8× against 38.3×. TG Therapeutics, Inc. grew revenue faster over the last twelve months: 76.1% against 22.6%. TG Therapeutics, Inc. has the higher net margin (55.2% vs 54.8%) and the lower return on invested capital (10.7% vs 24.1%). Across the 20 metrics below, Krystal Biotech, Inc. leads on 11 and TG Therapeutics, Inc. on 9.

Valuation

Metric KRYS TGTX Biotechnology median
P/E 38.28 17.75 8.50
P/S 21.22 9.57 9.71
P/B 6.88 12.67 2.13
Price to free cash flow 36.26 440.11 20.82
EV/EBITDA 41.59 57.69 0.64
EV/Sales 19.30 9.81 9.21
Earnings yield 2.61% 5.63% (33.15%)
Free cash flow yield 2.76% 0.23% (25.50%)

Profitability

Metric KRYS TGTX Biotechnology median
Gross margin 94.64% 82.37% 65.16%
Operating margin 44.89% 17.05% 0.00%
Net margin 54.82% 55.22% 0.00%
Free cash flow margin 58.52% 2.17% 0.00%
Return on equity 20.12% 100.28% (56.36%)
Return on assets 18.30% 37.70% (48.04%)
Return on invested capital 24.07% 10.69% 0.00%

Growth

Metric KRYS TGTX Biotechnology median
Revenue growth (TTM) 22.63% 76.08% 6.02%
EPS growth (last fiscal year) 128.00% 1,746.67% 30.26%
Revenue growth, 5-year CAGR — 426.73% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KRYS TGTX Biotechnology median
Debt to equity 0.00 1.23 0.00
Current ratio 8.32 4.27 4.72
Net debt to EBITDA (4.93) 0.86 0.96

Dividend

Metric KRYS TGTX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KRYS TGTX Biotechnology median
Market cap 9.77b 8.57b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack